Latest News on IMVT

Financial News Based On Company


Advertisement
Advertisement

Immunovant director Atul Pande sells $108,000 in stock By Investing.com

https://uk.investing.com/news/stock-market-news/immunovant-director-atul-pande-sells-108000-in-stock-93CH-4979927
Immunovant director Atul Pande sold 3,000 shares of company stock for $108,000 after exercising options. The transaction was part of a Rule 10b5-1 trading plan adopted in December 2025. Following the sale, Pande directly holds 116,731 shares and indirectly 20,000 shares through a trust.

Form 4 Roivant Sciences Ltd.: Eric Venker (President & Immunovant CEO) For: 10 November

https://ca.investing.com/news/stock-market-news/form-4-roivant-sciences-ltd-eric-venker-president--immunovant-ceo-for-10-november-93CH-4954956
This article reports on a Form 4 filing for Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., specifically for transactions that occurred on November 10. The filing likely details changes in his beneficial ownership of company securities. The article includes stock symbols IMVT and ROIV.

Why Immunovant (IMVT) Is Up 15.1% And What's Next

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/why-immunovant-imvt-is-up-151-and-whats-next
Immunovant (IMVT) saw a 15.1% increase following its Q2 report, which included a net loss of US$97.25 million but positive topline data for IMVT-1402 in rheumatoid arthritis and early commercial revenue for LISRAYA. The company also announced a US$150 million at-the-market equity program and a broad shelf registration to fund further development and commercial expansion. The market's focus now shifts to how these developments will impact Immunovant's investment narrative, particularly with IMVT-1402's progress and LISRAYA's market traction.

Immunovant (IMVT) Q2 2027 Earnings Call Transcript

https://www.theglobeandmail.com/investing/markets/markets-news/motley/8747214/immunovant-imvt-q2-2027-earnings-call-transcript/
Immunovant reported strong Q2 2027 results, with its lead candidate IMVT-1402 demonstrating significant efficacy in a Phase 2 trial for difficult-to-treat rheumatoid arthritis. The company also announced a strategic shift away from Sjögren’s disease development due to competitor data and market changes. Roivant, the parent company, successfully launched LISRAYA, generating $31.0 million in initial revenue, and anticipates major data readouts for Graves’ disease and myasthenia gravis in 2027.

HanAll Biopharma Shares Surge 20% After Partner Meets Primary Endpoint in Clinical Trial

https://finance.biggo.com/news/ce68f2fa-a01f-43f7-a827-f4e2296221be
Shares of HanAll Biopharma surged over 20% after its global partner, Immunovant, announced that a clinical trial for a difficult-to-treat rheumatoid arthritis treatment met its primary endpoint. The drug, imeroprubart, showed a significantly higher ACR20 response rate compared to placebo, leading to expectations of continued gains and discussions with the FDA for follow-on development. Immunovant also reported better-than-expected fiscal second-quarter results, further boosting investor confidence.
Advertisement

Why Is Immunovant Stock Soaring Today? - Immunovant (NASDAQ:IMVT)

https://www.benzinga.com/markets/biotech/26/11/63052244/immunovant-meets-primary-endpoint-in-difficult-to-treat-rheumatoid-arthritis-study
Immunovant (NASDAQ: IMVT) shares are soaring today after the company announced positive efficacy results from a clinical trial for IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis. The 600 mg dose met its primary endpoint, paving the way for regulatory discussions with the FDA. While the company will not advance IMVT-1402 further in SjD, it anticipates topline data from other registrational studies in Graves’ disease and myasthenia gravis in 2027, and chronic inflammatory demyelinating polyneuropathy in 2028.

Immunovant, Inc. (IMVT) Tops Q2 EPS by 27c

https://www.streetinsider.com/Earnings/Immunovant%2C+Inc.+%28IMVT%29+Tops+Q2+EPS+by+27c/27311217.html
Immunovant, Inc. (NASDAQ: IMVT) announced its Q2 earnings, reporting an EPS of ($0.47). This figure surpassed analyst estimates of ($0.74) by $0.27, indicating a stronger financial performance than anticipated.

Form 8K Immunovant Inc For: 9 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-immunovantinc-for-9-november-93CH-4942733
Immunovant Inc. has filed a Form 8K for November 9, 2026. This filing is a standard regulatory announcement that provides investors with information regarding significant events that shareholders should know about. The article itself serves as a brief notification of this corporate action.

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026

https://www.manilatimes.net/2026/11/09/tmt-newswire/globenewswire/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-quarter-ended-september-30-2026/2465149
Immunovant reported corporate updates and financial results for its fiscal second quarter ended September 30, 2026. The company's IMVT-1402 600 mg met its primary endpoint in a trial for difficult-to-treat rheumatoid arthritis, with FDA discussions planned later this year for its registrational program. However, Immunovant is unlikely to advance IMVT-1402 further in Sjögren’s disease, while other clinical development timelines remain on track, and the company expects topline data for Graves' disease and myasthenia gravis in 2027, and CIDP in 2028.

Immunovant earnings ahead after CLE setback tests pipeline By Investing.com

https://ca.investing.com/news/stock-market-news/immunovant-earnings-ahead-after-cle-setback-tests-pipeline-93CH-4942133
Immunovant (IMVT) is set to report its fiscal second-quarter results with analysts expecting a loss of $0.74 per share and zero revenue. Investors will be closely watching for updates on the company's pipeline strategy, particularly regarding IMVT-1402, after a recent setback in its cutaneous lupus erythematosus (CLE) program and prior failures in thyroid eye disease. The company's cash runway and progress in other difficult-to-treat indications like rheumatoid arthritis, myasthenia gravis, and Graves' disease will be key areas of focus.
Advertisement

(IMVT) Price Dynamics and Execution-Aware Positioning

https://news.stocktradersdaily.com/news_release/134/IMVT_Price_Dynamics_and_Execution-Aware_Positioning_110126115401_1793595241.html
This article provides an AI-generated analysis of Immunovant Inc. (NASDAQ: IMVT), highlighting strong near-term sentiment but elevated downside risk due to a lack of long-term support signals. It outlines specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, complete with entry zones, targets, and stop losses. The analysis also includes a multi-timeframe signal breakdown for near-term, mid-term, and long-term horizons, indicating support and resistance levels.

Immunovant | 4: Statement of changes in beneficial ownership of securities-Officer Girao Tiago

https://www.moomoo.com/news/notice/1003055373/statement-of-changes-in-beneficial-ownership-of-securities-officer-girao
This article is a SEC Form 4 filing related to Immunovant, indicating a statement of changes in beneficial ownership of securities for officer Girao Tiago. The content suggests a standard regulatory disclosure without further details.

Form 4 Immunovant Inc: Tiago Girao (CFO) For: 28 October By Investing.com

https://au.investing.com/news/stock-market-news/form-4-immunovantinc-tiago-girao-cfo-for-28-october-93CH-4731373
This article from Investing.com reports on a Form 4 filing for Immunovant Inc, indicating that Tiago Girao, the CFO, made a transaction on October 28. The brief update is a standard financial news item, flagging an insider transaction for the company.

Form 4 Immunovant Inc: Jay S. Stout (CTO) For: 21 October By Investing.com

https://za.investing.com/news/stock-market-news/form-4-immunovantinc-jay-s-stout-cto-for-21-october-93CH-4523692
This article from Investing.com reports on a Form 4 filing for Immunovant Inc, specifically detailing an insider transaction by Jay S. Stout, the company's CTO, for October 21. The article provides minimal textual content beyond the headline and timestamp, referring to the financial disclosure.

Immunovant CTO Jay Stout sells $75,099 in shares

https://in.investing.com/news/stock-market-news/immunovant-cto-jay-stout-sells-75099-in-shares-93CH-5652438
Jay S. Stout, CTO of Immunovant, Inc., sold 2,595 shares of the company's common stock for $75,099 on October 21, 2026. This "sell to cover" transaction was executed to fulfill tax withholding obligations related to vested restricted stock units and was not a discretionary sale. The biotechnology company, valued at $6 billion, faces challenges with a failed clinical trial for IMVT-1402 but maintains Buy and Overweight ratings from analysts.
Advertisement

Immunovant, Inc. Estimates – NASDAQ:IMVT

https://www.tradingview.com/symbols/NASDAQ-IMVT/financials-estimates/
This article provides access to financial actuals and estimates for Immunovant, Inc. (IMVT) on the NASDAQ Stock Market. Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates. The platform also visualizes trends over time for both annual and quarterly data.

Form 4 Roivant Sciences Ltd.: Eric Venker (President & Immunovant CEO) For: 20 October

https://ca.investing.com/news/stock-market-news/form-4-roivant-sciences-ltd-eric-venker-president--immunovant-ceo-for-20-october-93CH-4898245
This article reports on a Form 4 filing for Roivant Sciences Ltd., specifically concerning Eric Venker, who holds positions as President and Immunovant CEO. The filing is noted for activity on October 20th. The brief news item also mentions the stock symbols IMVT and ROIV, showing their respective percentage changes.

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

https://www.streetinsider.com/Press+Releases/Immunovant%C2%A0to%C2%A0Report+Financial+Results+for+the%C2%A0Second%C2%A0Fiscal+Quarter+Ended%C2%A0September%C2%A030%2C+2026%2C%C2%A0and+Provide+Business+Update%C2%A0on%C2%A0Monday%2C+November+9%2C+2026/27212787.html
Immunovant, Inc. announced it will report its financial results for the second fiscal quarter ended September 30, 2026, on Monday, November 9, 2026, before the market opens. Roivant Sciences Ltd., Immunovant's majority stockholder, will host a conference call and webcast at 8:00 a.m. ET on the same day, which will include a business update for Immunovant. The company is a clinical-stage immunology company focused on developing therapies for autoimmune diseases.

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

https://www.moomoo.com/news/post/1001859253/immunovant-to-report-financial-results-for-the-second-fiscal-quarter
Immunovant (NASDAQ: IMVT) announced that it will release its financial results for the second fiscal quarter, which ended on September 30, 2026, on Monday, November 9, 2026. The company will also provide a business update on the same day. This report will offer investors insights into Immunovant's financial performance and strategic progress for the recent quarter.

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

https://www.morningstar.com/news/globe-newswire/9850117/immunovant-to-report-financial-results-for-the-second-fiscal-quarter-ended-september-30-2026-and-provide-business-update-on-monday-november-9-2026
Immunovant, Inc. (Nasdaq: IMVT) announced it will report its financial results for the second fiscal quarter ended September 30, 2026, on Monday, November 9, 2026, before the market opens. Roivant Sciences Ltd. (Nasdaq: ROIV), Immunovant’s majority stockholder, will host a conference call and webcast at 8:00 a.m. ET on the same day, which will include a business update for Immunovant. Immunovant is a clinical-stage immunology company focused on developing therapies for autoimmune diseases.
Advertisement

Immunovant, Inc. (IMVT) Options Chain

https://ca.finance.yahoo.com/quote/IMVT/options/?date=1799971200&straddle=false&type=all
This page provides the options chain for Immunovant, Inc. (IMVT), displaying real-time stock information and delayed options data. It lists call and put options, but currently shows no available contracts for either category. The page also includes general market data and related financial news links.

Immunovant stops lupus development and H.C. Wainwright keeps Buy rating on Immunovant stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/immunovant-stops-lupus-development-and-h-c-wainwright-keeps-buy-rating-on-immunovant-stock/70334666
Immunovant (IMVT) ceased development of IMVT-1402 for cutaneous lupus after a 57-patient study missed its primary endpoint on September 23, 2026. Despite this setback, H.C. Wainwright maintained a Buy rating and a $41.00 price target for the stock. The company continues to develop IMVT-1402 for five other indications, and its next earnings report is scheduled for November 18, 2026.

Immunovant Q1 2027 Earnings Call: Complete Transcript

https://www.benzinga.com/news/26/10/62346043/immunovant-q1-2027-earnings-call-complete-transcript
Immunovant (NASDAQ: IMVT) held its first-quarter earnings conference call, anticipating a busy second half of 2026 with multiple data readouts and potential product launches. The company expects to launch brepocitinib by the end of September following priority review and a PDUFA date this quarter, while also progressing phase 3 studies for cutaneous sarcoidosis and lichen planopilaris. Immunovant reported strong financial health with nearly $4 billion in cash and significant share repurchase activity, and ongoing litigation with Pfizer and BioNTech after a $950 million settlement with Moderna.

Form 4 Roivant Sciences Ltd.: Eric Venker (President & Immunovant CEO) For: 30 September

https://ca.investing.com/news/stock-market-news/form-4-roivant-sciences-ltd-eric-venker-president--immunovant-ceo-for-30-september-93CH-4877115
This article reports on a Form 4 filing for Roivant Sciences Ltd., detailing transactions made by Eric Venker, who serves as President and CEO of Immunovant. The filing specifically covers activity up to September 30th. The brief announcement provides a direct reference to the regulatory document.

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-immunovant-inc-to-contact-law-firm-302906196.html
Kuehn Law, PLLC is investigating whether officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders through potential self-dealing. Long-term IMVT stockholders are encouraged to contact the firm for a free consultation, as they may be entitled to damages and corporate governance reforms. The firm emphasizes that shareholder participation is crucial for maintaining integrity in financial markets.
Advertisement

Understanding Momentum Shifts in (IMVT)

https://news.stocktradersdaily.com/news_release/10/Understanding_Momentum_Shifts_in_IMVT_101226023601_1791830161.html
The article analyzes Immunovant Inc. (NASDAQ: IMVT), indicating weak near and mid-term sentiment despite a positive long-term outlook. It highlights a current breakdown that could lead to lower prices and elevated downside risk. The report provides AI-generated trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

https://www.morningstar.com/news/pr-newswire/20261012ny70328/kuehn-law-encourages-investors-of-immunovant-inc-to-contact-law-firm
Kuehn Law, PLLC is investigating Immunovant, Inc. (NASDAQ: IMVT) regarding potential breaches of fiduciary duties by certain officers and directors due to alleged self-dealing. The firm is encouraging long-term IMVT shareholders to contact them to discuss potential damages and corporate governance reforms, offering free consultations and covering all case costs. Shareholders are advised to act promptly to enforce their rights.

Bronstein, Gewirtz & Grossman, LLC Initiate an Investigation into Allegations Against Immunovant, Inc. (IMVT) And Encourages Shareholders to Reach Out

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiate-an-investigation-int-1231546
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Immunovant, Inc. (IMVT) after the company announced its IMVT-1402 study for cutaneous lupus erythematosus failed to meet its primary endpoint, causing a 7.37% stock drop. The firm encourages shareholders to reach out to assist with the investigation. This action aims to recover investor capital and ensure corporate accountability.

IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law

https://www.businesswire.com/news/home/20261011801778/en/IMVT-Investors-with-%24100000-in-Losses-Have-Opportunity-to-Join-Immunovant-Inc.-Fraud-Investigation-with-SBS-Law
Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Immunovant, Inc. (NASDAQ: IMVT) on behalf of investors who suffered losses. This probe follows Immunovant's announcement on September 23, 2026, that its IMVT-1402 proof-of-concept study failed to meet its primary endpoint, leading to a nearly 7.4% drop in the company's stock. SBS is seeking to determine if Immunovant issued misleading statements or withheld pertinent information from investors.

IMVT: Immunovant Inc Latest Stock Price, Analysis, News and Trading Ideas

https://stocktwits.com/symbol/IMVT
This page provides a snapshot of Immunovant Inc (IMVT) stock, including its latest price, market capitalization, and key financial metrics. It also features a sentiment analysis and an analyst's note highlighting institutional accumulation despite a recent clinical trial setback. The article suggests that large investors view the trial failure as indication-specific rather than a platform-wide issue.
Advertisement

Immunovant COO Melanie Gloria sells shares worth $71,846

https://www.investing.com/news/insider-trading-news/immunovant-coo-melanie-gloria-sells-shares-worth-71846-93CH-4941810
Immunovant COO Melanie Gloria sold 2,241 shares of the company's stock for $71,846 on October 7, 2026, primarily to cover tax obligations from vested restricted stock units. This "sell to cover" transaction was not discretionary. The company has recently faced setbacks, including halting development of a drug candidate for cutaneous lupus erythematosus, though analysts have maintained "Buy" and "Overweight" ratings.

Immunovant COO Melanie Gloria sells shares worth $71,846

https://in.investing.com/news/stock-market-news/immunovant-coo-melanie-gloria-sells-shares-worth-71846-93CH-5626610
Immunovant COO Melanie Gloria sold 2,241 shares of the company's common stock for $71,846 on October 7, 2026. This transaction was a "sell to cover" to satisfy tax withholding obligations related to the vesting of restricted stock units and not a discretionary sale. The sale comes amid other company developments, including the halt of a drug candidate's development and mixed analyst ratings.

Immunovant chief legal officer Van Tuyl sells $42,543 in stock

https://in.investing.com/news/stock-market-news/immunovant-chief-legal-officer-van-tuyl-sells-42543-in-stock-93CH-5626632
Immunovant's Chief Legal Officer, Christopher Van Tuyl, sold 1,327 shares of common stock for $42,543 to cover tax withholding obligations related to restricted stock units. Following the sale, he still beneficially owns 175,218 shares. This transaction occurred amidst a 9% decline in IMVT shares over the past week, though the stock has seen a 74% return over the last year.

Immunovant CTO Jay Stout sells $122,116 in shares

https://www.investing.com/news/insider-trading-news/immunovant-cto-jay-stout-sells-122116-in-shares-93CH-4941863
Immunovant's Chief Technology Officer, Jay S. Stout, sold 3,809 shares of common stock totaling $122,116 on October 7, 2026. These transactions were "sell to cover" sales to meet tax obligations related to restricted stock units vesting and not discretionary sales. Despite a recent 9% pullback, Immunovant's stock has surged nearly 79% over the past year but is considered overvalued by InvestingPro's analysis.

Form 4 Immunovant Inc For: 9 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-immunovantinc-for-9-october-93CH-2729854
This article announces the filing of Form 4 for Immunovant Inc. on October 9th. It is a brief news item indicating a regulatory filing has been made for the company. The article also provides current stock market data and other related financial news.
Advertisement

Form 4 Immunovant Inc For: 9 October By Investing.com

https://za.investing.com/news/stock-market-news/form-4-immunovantinc-for-9-october-93CH-4498061
This article from Investing.com announces a Form 4 filing for Immunovant Inc. related to activity on October 9th. It is a brief, data-driven update, common for financial news platforms reporting on insider transactions or significant company filings. The content primarily serves as an alert to investors about this specific financial disclosure.

Form 4 Immunovant Inc For: 9 October

https://in.investing.com/news/stock-market-news/form-4-immunovantinc-for-9-october-93CH-5626617
This article announces the filing of a Form 4 for Immunovant Inc on October 9. The Form 4 is a regulatory filing used to disclose changes in beneficial ownership of a company's securities by its insiders. The article itself provides no further details beyond the filing announcement.

Form 4 Immunovant Inc For: 5 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-immunovantinc-for-5-october-93CH-2722598
The article reports that Immunovant Inc. filed a Form 4 for October 5th. This filing is a regulatory document detailing changes in stock ownership by company insiders. Further specifics regarding the content of the Form 4 are not provided within the article.

Immunovant CEO Eric Venker sells $119,589 in shares By Investing.com

https://ng.investing.com/news/stock-market-news/immunovant-ceo-eric-venker-sells-119589-in-shares-93CH-2722591
Immunovant CEO Eric Venker sold 3,506 shares of company stock for $119,589 to cover tax obligations from vested equity awards, not as a discretionary sale. This transaction followed the settlement of Capped Value Appreciation Rights, where Venker acquired and then disposed of a larger number of shares. Despite recent challenges, including a drug candidate setback, Immunovant's stock has seen significant returns, and analysts maintain positive ratings.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Immunovant, Inc. (IMVT) And Encourages Investors to Connect

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-immunovant-i-1231542
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Immunovant, Inc. (NASDAQ:IMVT) after the company announced that a proof-of-concept study for its drug IMVT-1402 did not achieve statistical significance, leading to a 7.37% stock price drop. The firm encourages investors to connect to assist with the investigation into Immunovant securities.
Advertisement

Form 4 Immunovant Inc For: 5 October By Investing.com

https://za.investing.com/news/stock-market-news/form-4-immunovantinc-for-5-october-93CH-4490893
This article from Investing.com reports on a Form 4 filing for Immunovant Inc (IMVT) related to transactions on October 5. It is a brief, factual notice acknowledging the financial disclosure. The article simply states the filing and the date it pertains to.

Form 4 Immunovant Inc For: 5 October By Investing.com

https://au.investing.com/news/stock-market-news/form-4-immunovantinc-for-5-october-93CH-4673811
This article from Investing.com reports on a Form 4 filing for Immunovant Inc for October 5th. It is a brief financial news item indicating a regulatory filing has been made for the company. The article provides the company's stock symbol (IMVT) and its recent percentage change.

Immunovant CEO Eric Venker sells $119,589 in shares By Investing.com

https://ca.investing.com/news/stock-market-news/immunovant-ceo-eric-venker-sells-119589-in-shares-93CH-4866746
Immunovant CEO Eric Venker sold 3,506 shares of company stock for $119,589 on October 2, 2026, to cover tax obligations related to vested equity awards. This "sell to cover" transaction was not discretionary. The sale followed the settlement of Capped Value Appreciation Rights (CVARs) on October 1, 2026, where Venker acquired 92,187 shares and disposed of 85,886 shares.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Immunovant, Inc. (IMVT) and Encourages Stockholders to Learn More About the Investigation

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1231541
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Immunovant, Inc. (IMVT) following a significant stock drop. This occurred after the company announced on September 23, 2026, that its IMVT-1402 study for cutaneous lupus erythematosus did not meet its primary endpoint, leading to a decision to halt further development for that indication. The firm encourages affected investors to learn more about the investigation and potentially participate in a class action lawsuit.

Form 4 Immunovant Inc For: 5 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-immunovantinc-for-5-october-93CH-4866753
This article announces the filing of Form 4 for Immunovant Inc. on October 5th, indicating insider transactions. It is a brief financial news item from Investing.com and includes the stock symbol IMVT, which showed a -4.66% change at the time of publication.
Advertisement

Bronstein, Gewirtz & Grossman, LLC Encourages Immunovant, Inc. (IMVT) Investors to Inquire about Securities Investigation

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-immunovant-inc.-im-1231540
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors in Immunovant, Inc. (IMVT) following a significant stock drop. This investigation comes after Immunovant announced on September 23, 2026, that its IMVT-1402 study for cutaneous lupus erythematosus failed to meet its primary endpoint, leading the company to halt further development of the drug for that indication. The firm is encouraging affected investors to inquire about the securities investigation through their website or by contacting them directly.

Immunovant, Inc. (IMVT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/immunovant-inc.-imvt-investigation-bronstein-gewirtz-and-grossma-1226778
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Immunovant, Inc. (IMVT) after the company announced its proof-of-concept study for IMVT-1402 in cutaneous lupus erythematosus failed to achieve statistical significance, causing a 7.37% stock drop. The firm encourages investors to contact them to learn more about the investigation and potential class action lawsuit.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Immunovant, Inc. (IMVT) and Encourages Stockholders to Learn More About the Investigation

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1226777
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Immunovant, Inc. (IMVT) following a 7.37% stock price drop on September 23, 2026. This decline occurred after Immunovant's IMVT-1402 study for cutaneous lupus erythematosus failed to meet its primary endpoint, leading the company to halt further development for that indication. The law firm is encouraging investors who purchased Immunovant securities to join the investigation into potential claims.

Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case

https://www.insidermonkey.com/news/immunovant-imvt-one-trial-failure-doesnt-break-the-bull-case-1844798/?amp=1
Immunovant (IMVT) experienced a setback with its IMVT-1402 trial for cutaneous lupus erythematosus (CLE), failing to meet its primary endpoint. Despite this, analysts believe the company's bull case remains intact due to five other ongoing IMVT-1402 programs for various autoimmune diseases, strong cash reserves, and increasing hedge fund interest. The company expects topline data from registrational trials in Graves’ disease and myasthenia gravis in 2027.

Immunovant CLO Christopher Van Tuyl Executes Mandatory Sale of 2,846 Shares for Tax Withholding

https://kalkinemedia.com/us/news/announcements/immunovant-clo-christopher-van-tuyl-executes-mandatory-sale-of-2846-shares-for-tax-withholding
Christopher Van Tuyl, Immunovant's Chief Legal Officer, sold 2,846 shares of company common stock on September 23, 2026. This mandatory sale, at a weighted average price of $36.36 per share, was conducted to cover tax withholding obligations arising from the vesting of 6,872 restricted stock units (RSUs) on September 16, 2026. This transaction was non-discretionary and part of the issuer's "sell to cover" policy, leaving Van Tuyl with 176,545 directly owned shares.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement